Transthyretin-mediated amyloid cardiomyopathy (attr-CM)
Clinical trials for Transthyretin-mediated amyloid cardiomyopathy (attr-CM) explained in plain language.
Never miss a new study
Get alerted when new Transthyretin-mediated amyloid cardiomyopathy (attr-CM) trials appear
Sign up with your email to follow new studies for Transthyretin-mediated amyloid cardiomyopathy (attr-CM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Heart scan study sees if new drug clears sticky proteins
Disease control CompletedThis study looks at whether the drug eplontersen can reduce abnormal protein buildup in the heart for people with a condition called ATTR-CM. About 150 participants from a larger trial will get heart scans after 140 weeks of treatment. The goal is to see if the drug helps clear t…
Matched conditions: TRANSTHYRETIN-MEDIATED AMYLOID CARDIOMYOPATHY (ATTR-CM)
Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Can a new injection slow a rare heart disease?
Disease control CompletedThis trial is testing an experimental drug called eplontersen in people with transthyretin-mediated amyloid cardiomyopathy (ATTR CM), a condition where abnormal protein builds up in the heart and leads to heart failure. The study aims to see if the drug, given as a regular inject…
Matched conditions: TRANSTHYRETIN-MEDIATED AMYLOID CARDIOMYOPATHY (ATTR-CM)
Phase 3 • Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Heart scans reveal hidden protein buildup in rare disease
Knowledge-focused CompletedThis study uses MRI scans to measure amyloid protein buildup in the hearts of up to 150 people with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). Participants are already enrolled in a larger treatment trial. The goal is to see how amyloid levels change over time, not …
Matched conditions: TRANSTHYRETIN-MEDIATED AMYLOID CARDIOMYOPATHY (ATTR-CM)
Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC